12:00 AM
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VXM01: Phase I/II data

Top-line data from the dose-escalation, double-blind, placebo-controlled, German Phase I/II VXM01-01-DE trial in 45 patients with locally advanced, inoperable, stage IV pancreatic cancer showed that 4 vaccinations with oral VXM01 plus gemcitabine given over 7 days were well tolerated with no dose-limiting toxicities (DLTs) reported and thus met the primary safety endpoint. Vaximm said that VXM01 plus gemcitabine...

Read the full 266 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >